Opportunity is Coming for Your Child with PFIC!
Albireo Pharma is in the midst of preparing for an exciting Phase 3 clinical trial to test A4250 for the treatment of progressive familial intrahepatic
- Rare Disease News
PFIC Advocacy & Resource Network
PFIC Advocacy & Resource Network
The PFIC Network works hard to not only understand Progressive Familial Intrahepatic Cholestasis (PFIC), but also the needs of the PFIC community. To document these needs in an effort to fill knowledge and resource gaps. Our organization is based in the US; however, our efforts extend internationally as we continue to work with families in all areas of the world to assist in finding solutions for our rare community. We plan to further our organizations mission by continuing to provide programs, advocate, work to advance research, and support the needs of the patient and healthcare community. Together, we will make a difference.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
- Progressive Familial Intrahepatic Cholestasis (PFIC)
Patient Worthy Posts on Progressive Familial Intrahepatic Cholestasis (PFIC)
Half of Children with PFIC will Receive a Liver Transplant by Age 10, Study Finds
An international team of researchers studying the effects of progressive familial intrahepatic cholestasis (PFIC) in children have found that half of the children had received
Phase 3 Trials for an Investigational Progressive Familial Intrahepatic Cholestasis Drug are Gearing Up
According to a story from Financial Buzz, the pharmaceutical company Albireo Pharma recently announced that the first patient has been enrolled in its Phase 3
An Experimental Treatment For PFIC Has Been Awarded Rare Pediatric Disease Designation by the FDA
The U.S. Food and Drug Administration has granted the experimental drug A4250 rare paediatric disease designation for the treatment of progressive familial intrahepatic cholestasis. The
A Potential Drug for Progressive Familial Intrahepatic Cholestasis Achieves Fast Track Designation
The United States Food and Drug Administration has granted Fast Track designation to a drug being researched as a potential treatment for progressive familial intrahepatic
New Development Deal Struck for Experimental Alagille Syndrome Treatment
According to a story from prnewswire.com, the drug developer Mirum Pharmaceuticals recently announced that is has entered an agreement with Shire which grants exclusive rights
